登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《bioRxiv，4月3日，SARS-CoV-2 neutralizing serum antibodies in cats: a serological investigation》

  • 来源专题：COVID-19科研动态监测
  • 编译者： xuwenwhlib
  • 发布时间：2020-04-05

  • SARS-CoV-2 neutralizing serum antibodies in cats: a serological investigation

    Qiang Zhang, Huajun Zhang, Kun Huang, Yong Yang, Xianfeng Hui, Jindong Gao, Xinglin He, Chengfei Li, Wenxiao Gong, Yufei Zhang, Cheng Peng, Xiaoxiao Gao, Huanchun Chen, Zhong Zou, Zhengli Shi, Meilin Jin

    doi: https://doi.org/10.1101/2020.04.01.021196

    Abstract

    Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in Wuhan, China, and rapidly spread worldwide. Previous studies suggested cat could be a potential susceptible animal of SARS-CoV-2. Here, we investigated the infection of SARS-CoV-2 in cats by detecting specific serum antibodies. A cohort of serum samples were collected from cats in Wuhan, including 102 sampled after COVID-19 outbreak, and 39 prior to the outbreak. 15 of 102 (14.7%) cat sera collected after the outbreak were positive for the receptor binding domain (RBD) of SARS-CoV-2 by indirect enzyme linked immunosorbent assay (ELISA). Among the positive samples, 11 had SARS-CoV-2 neutralizing antibodies with a titer ranging from 1/20 to 1/1080. No serological cross-reactivity was detected between the SARS-CoV-2 and type I or II feline infectious peritonitis virus (FIPV). Our data demonstrates that SARS-CoV-2 has infected cat population in Wuhan during the outbreak.

    *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.

  • 原文来源：https://www.biorxiv.org/content/10.1101/2020.04.01.021196v1
44浏览量
原文链接
相关报告

  • 《Science，9月2日，A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-09-15
    • A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations Ludivine Grzelak1,2,3,*, Sarah Temmam4,*, Cyril Planchais5,*, Caroline Demeret6,7,*, Laura Tondeur8, Christèle H See all authors and affiliations Science Translational Medicine 02 Sep 2020: Vol. 12, Issue 559, eabc3103 DOI: 10.1126/scitranslmed.abc3103 Abstract It is of paramount importance to evaluate the prevalence of both asymptomatic and symptomatic cases of SARS-CoV-2 infection and their differing antibody response profiles. Here, we performed a pilot study of four serological assays to assess the amounts of anti–SARS-CoV-2 antibodies in serum samples obtained from 491 healthy individuals before the SARS-CoV-2 pandemic, 51 individuals hospitalized with COVID-19, 209 suspected cases of COVID-19 with mild symptoms, and 200 healthy blood donors. We used two ELISA assays that recognized the full-length nucleoprotein (N) or trimeric spike (S) protein ectodomain of SARS-CoV-2. In addition, we developed the S-Flow assay that recognized the S protein expressed at the cell surface using flow cytometry, and the luciferase immunoprecipitation system (LIPS) assay that recognized diverse SARS-CoV-2 antigens including the S1 domain and the carboxyl-terminal domain of N by immunoprecipitation. We obtained similar results with the four serological assays. Differences in sensitivity were attributed to the technique and the antigen used. High anti–SARS-CoV-2 antibody titers were associated with neutralization activity, which was assessed using infectious SARS-CoV-2 or lentiviral-S pseudotype virus. In hospitalized patients with COVID-19, seroconversion and virus neutralization occurred between 5 and 14 days after symptom onset, confirming previous studies. Seropositivity was detected in 32% of mildly symptomatic individuals within 15 days of symptom onset and in 3% of healthy blood donors. The four antibody assays that we used enabled a broad evaluation of SARS-CoV-2 seroprevalence and antibody profiling in different subpopulations within one region.
    33浏览量
    原文链接

  • 《Science，12月4日，Robust neutralizing antibodies to SARS-CoV-2 infection persist for months》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-12-22
    • Robust neutralizing antibodies to SARS-CoV-2 infection persist for months View ORCID ProfileAnia Wajnberg1,*, View ORCID ProfileFatima Amanat2,3, Adolfo Firpo4, View ORCID ProfileDeena R. Altman5, Mark J. Bailey1, View ORCID ProfileMayce Mansour1,... Science  04 Dec 2020: Vol. 370, Issue 6521, pp. 1227-1230 DOI: 10.1126/science.abd7728 Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic with millions infected and more than 1 million fatalities. Questions regarding the robustness, functionality, and longevity of the antibody response to the virus remain unanswered. Here, on the basis of a dataset of 30,082 individuals screened at Mount Sinai Health System in New York City, we report that the vast majority of infected individuals with mild-to-moderate COVID-19 experience robust immunoglobulin G antibody responses against the viral spike protein. We also show that titers are relatively stable for at least a period of about 5 months and that anti-spike binding titers significantly correlate with neutralization of authentic SARS-CoV-2. Our data suggest that more than 90% of seroconverters make detectable neutralizing antibody responses. These titers remain relatively stable for several months after infection.
    17浏览量
    原文链接